key: cord-0875168-egb13koo
authors: Durkee-Shock, Jessica; Lazarski, Christopher A.; Jensen-Wachspress, Mariah A.; Zhang, Anqing; Son, Aran; Kankate, Vaishnavi V.; Field, Naomi E.; Webber, Kathleen; Lang, Haili; Conway, Susan R.; Hanley, Patrick J.; Bollard, Catherine M.; Keller, Michael D.; Schwartz, Daniella M.
title: Transcriptomic analysis reveals optimal cytokine combinations for SARS-CoV-2 Specific T cell therapy products
date: 2022-04-29
journal: Mol Ther Methods Clin Dev
DOI: 10.1016/j.omtm.2022.04.013
sha: 1a0c44f5395bab2df5f4bc6acbb2a344ea1bb41a
doc_id: 875168
cord_uid: egb13koo

Adoptive T cell immunotherapy has been used to restore immunity against multiple viral targets in immunocompromised patients after bone marrow transplantation and has been proposed as a strategy for preventing COVID-19 in this population. Ideally, expanded SARS-CoV-2 virus-specific T cells (CSTs) should demonstrate marked cell expansion, T cell specificity, and CD8+ T cell skewing prior to adoptive transfer. However, current methodologies using IL-4+IL-7 result in suboptimal specificity, especially in CD8+ cells. Using a microexpansion platform, we screened various cytokine cocktails (IL-4+IL-7, IL-15, IL-15+IL-4, IL-15+IL-6, and IL-15+IL-7) for the most favorable culture conditions. IL-15+IL-7 optimally balanced T cell expansion, polyfunctionality, and CD8+ T cell skewing of a final therapeutic T cell product. Additionally, the transcriptomes of CD4+ and CD8+ T cells cultured with IL-15+IL-7 displayed the strongest induction of antiviral type I interferon (IFN) response genes. Subsequently, microexpansion results were successfully translated to a GMP-applicable format where IL-15+IL-7 outperformed IL-4+IL-7 in specificity and expansion, especially in the desirable CD8+ T cell compartment. These results demonstrate the functional implications of IL-15, IL-4, and IL-7 containing cocktails for therapeutic T cell expansion, which could have broad implication for cellular therapy, and pioneers the use of RNA-seq to guide VST manufacturing.

During the COVID-19 pandemic, immunocompromised patients, including those with 56 malignancy, inborn errors of immunity, or on immunosuppression therapy have demonstrated 57 increased morbidity and mortality in the setting of SARS-CoV-2 infection. 1 2 3 4 5 6 T cell 58

Expansion with IL-4+IL-7 resulted in higher CD45RO -CCR7 + T cells (which may include both 124 naïve and stem cell memory) as compared with cultures containing IL-15. (Fig 1B) 125

In prior studies, polyfunctional antiviral specificity has been considered a key measure for 126 predicting therapeutic efficacy of adoptively transferred VSTs. 26 27 Amongst the five tested culture 127 conditions, IL15+IL-7 was comparable to IL-4+IL-7 at expanding polyfunctional virus-specific 128 TNF + IFN + CD4 + T cells, while IL-15+IL-4 was the least effective. (Fig 1C, Supp Fig 1) In the 129 CD8 + T cell compartment, IL-15-containing conditions increased the expansion of virus-specific 130 TNF + IFN + CD8 + T cells relative to IL-4+IL-7. This increase was significant in cells cultured 131 with IL-15 alone and with IL-15+IL-6, and there was a trend towards expansion of 132 TNF + IFN + CD8 + virus-specific T cells in IL-15+IL-4 and IL-15+IL-7 containing cultures. (Fig  133   1D , Supp Fig 1) . We also assessed antigen specific-specific surface expression of CD107a as a 134 marker of immune cell activation and cytotoxic degranulation. 28 29 30 31 No appreciable differences 135 in CST CD107a expression were observed of which cytokine cocktail was used. (Fig 1E) Taken 136 together, these microexpansion results suggest that IL-15+IL-7 might be superior to IL-4+IL-7 for 137 CST manufacture since IL-7 and IL-15 support the expansion of CD4 + and CD8 + virus-specific T 138 cells respectively. In contrast, our so-called "standard" approach using IL-4 and IL-7 results in a 139 CST product that predominantly favors CD4+ T cell expansion. In summary, IL-15+IL-7 140 improved CD8 + T cell expansion and specificity, while preserving CD4 + T cell expansion and 141 J o u r n a l P r e -p r o o f specificity as well as total T cell expansion (which were compromised in the other IL-15 containing 142 cytokine conditions) and thus was chosen for further 144 IL-15 + IL-7 conditions enhance interferon-response gene expression compared with IL-4 145 conditions. 146

Based on our observation that IL-15-containing conditions were more effective than IL-4+IL-7 at 147 inducing CD4 + and CD8 + antigen specific VSTs, we hypothesized that IL-15 might be a major 148 inducer of antiviral pathways. TNF and IFN production are both important predictors of 149 antiviral activity in T cells although largely driven by Type 1 interferon (IFN) responses. 32 Type 150 1 IFNs induce antiviral IFN-stimulated genes (ISGs) through the ISGF complex comprising 151 STAT1/STAT2/IRF9. To determine the effect of the different culture conditions on antiviral 152

ISGs, we measured the transcriptomes of CD4 + and CD8 + T cells derived from 4 donors 153 expanded without cytokines or with the five CST-promoting culture conditions. 154 155 In CD4 + T cells targeting SARS-CoV-2 Spike and Membrane proteins, CST expansion regulated 156 450 differentially expressed genes (DEGs) in >1 condition (Fig 2A) . CST expansion induced 157 genes important for viral defense across multiple culture conditions, indicating that expansion 158 upregulates desired antiviral responses in CD4 + T cells. Conversely, IL-4-containing culture 159 condition induced a gene cassette which was enriched for negative regulation of host defense, 160 suggesting that IL-4 might reduce the protective capacity of CD4 + T cells. As in CD4 + T cells, 161 CST expansion regulated three cassettes of genes in CD8 + T cells: a group of expansion-162 repressed genes, a set of common expansion-induced genes, and a cassette of genes induced 163 primarily in IL-4-containing cultures (Fig 2B) . The IL-4-induced gene cassette was enriched for 164 J o u r n a l P r e -p r o o f negative regulation of host defense (ARG2, TNFRSF11A) indicating that IL-4 might also inhibit 165 the immune function of CD8 + T cells. 166

To specifically investigate the antiviral transcriptomic signature of the different CSTs, we 168 investigated a cassette of ISGs critical for antiviral host defense across human diseases and 169 murine models. 33 Using Gene Set Enrichment Analysis (GSEA), we compared enrichment of 170 this cassette between the various culture conditions, finding that IL-15+IL-7 was the most 171 effective at inducing antiviral ISGs in both CD4 + and CD8 + T cells (Figs 2C and 2D , 172 respectively). 34 35 Accordingly, STAT1 target genes were also strongly enriched in CD4 + T cells 173 cultured with IL-15+IL-7, whereas STAT3 and STAT6 target genes were not enriched (Supp 174 15+IL-7 as compared to IL-4+IL-7, with a mean fold-expansion of 3.2 vs. 1.9 (p=.08). (Fig 3A) 189

More than 90% of lymphocytes generated with IL-4+IL-7 and IL-15+ IL-7 were CD3 + T cells, 190 with minimal presence of residual monocytes or B cells (Fig 3B) . Proportions of CD4 + and CD8 + 191 T cells were comparable between the 2 cytokine conditions. Reflecting microexpansion results, 192

cultures containing IL-15 demonstrated increased CD3 -CD56 + NK cells. (For median values and 193 interquartile ranges, please refer to Supp Table 3 ). CSTs cultured with IL-15+IL-7 had 194 proportionally higher EM (IL-4+IL-7 median 10.1%; IL-15+IL-7 median 48.1%) and TEMRA 195 cells (IL-4+IL-7 median 4.7%; IL-15+IL-7 median 6.2%), while central memory populations 196 were similar (IL-4+IL-7 median 15.9%; IL-15+IL-7 median 15.9%). (Fig 3C) . 197

Finally, VSTs cultured with IL-15+IL-7 showed increased CD8 + and CD4 + T cell specificity to 198 both membrane and spike peptide pools, without increasing nonspecific T cell activation. (Fig  199   3D and 3E) Additionally, IL-15+IL-7 cultures improved CST cytotoxicity as represented by 200

CD107a expression (Fig 3F) . Specificity testing via IFN + ELISpot after culture in IL-15+IL-7 201 similarly showed a trend towards higher specificity as compared with IL-4+IL-7. (Fig 3G) Here we have shown that antiviral specificity and the antiviral IFN transcriptome of CSTs can be 208 dramatically improved by optimizing the cytokines used for proliferation and differentiation 209 during cell culture. Multiple reports have demonstrated the importance of CD8 + T cells in natural 210 immunity to In those studies, patients with CD8 + T cell lymphopenia had worse 211 disease, while robust CD8 + T cell responses were associated with better outcomes. 18 19 Our work 212 demonstrates that expansion of a SARS-CoV2 specific T cell product results in different CD4 + 213 and CD8 + T cell populations when using IL-4+IL-7 versus IL-15+IL-7. The latter combination 214 improved expansion, shifted the memory phenotype, improved specificity in the CD8 + T cell 215 compartment, and increased antigen specific CD107a expression. Together, these results suggest 216 a more effective CD8 + T cell response after culture with IL-15+IL-7, which should enhance 217 clinical potency of this novel therapeutic in vivo. Of note, while cytotoxicity of CSTs cultured 218 with IL-7+IL-15 was not demonstrated, cytotoxicity assays reflect only a single effector function 219 of VSTs. Furthermore, peptide-pulsed PHA blasts were used as the target cells because a 220 validated pulmonary model for target cells is not currently available. Since SARS-CoV-2 does 221 not have a prominent viremia, even in immunocompromised hosts, cytotoxicity of hematologic 222 cells, or lack thereof, is unlikely to be clinically relevant. As expected, expansion of CD56 + CD3 -223 NK cells increased in the setting of IL-15+IL-7 given the role of IL-15 in the proliferation and 224 maturation of both CD8 + T cells and NK cells. 38 While NK cells are typically rare in a T cell 225 therapeutic product, NK cells may be clinically beneficial here due to their importance in natural 226 SARS-CoV-2 immunity. 39 NK therapy is also being considered independently for SARS-CoV-227 2 therapy; thus, a joint NK and T cell specific product may further reconstitute viral-specific 228 immunity in patients with high-risk immunocompromised states (NCT04280224, 229 NCT04365101). 40 230 231

The type I interferon / antiviral transcriptome of viral specific T cell products for adoptive 232 immunotherapy has not been previously assessed, although RNA seq has been used extensively 233 to understand the efficacy and differential responses to CAR-T cells and other anti-tumor T cells. 234 41 42 43 44 Here, we successfully demonstrated that IL-15+IL-7 maximally enhanced expression of 235 desirable ISG cassettes for cell replication and viral defense, as well as STAT1 target genes. In 236 comparison, cocktails containing IL-4 induced genes that repressed host defense as well as 237 undesirable, atopic Type II immune response genes, especially in CD8 + T cells. This reflects 238 prior studies reporting deleterious effects of type II cytokines on CD8 + T cell responses. 45 Although this study systematically investigated the efficacy of multiple conditions on CST 258 expansion, the focus on SARS-CoV2-specific T cells raises the possibility that these findings 259 may not be generalizable to other viral targets. For instance, IL-15+IL-6 was previously found to 260 be optimal for CMV-specific T cell expansion . 17 Given the possible role of IL-6 in severe 261 COVID-19, IL-6 was felt to be undesirable for CST product development, but may not be as 262 concerning for other viral targets. 48 We anticipate that this platform and VST product analysis, 263 both using RNA-seq and high-throughput cytokine screening, could be used for optimizing VST 264 production for many other viral targets of interest. This study was also performed on a relatively On day 10, expanded VSTs from 4 donors were restimulated with SARS-CoV-2 pepmixes 342 encompassing spike, nucleocapsid, membrane, and envelope with CD28/CD49d (BD 343 Biosciences) and incubated for 4 hours. Cell viability was assessed using Live-Dead near IR. 344

VSTs were surface stained with fluorophore-conjugated antibodies against CD4-BV605, CD8-345 BV421, CD19-FITC, CD16-FITC, and CD14-FITC (Biolegend), and then sorted for CD4 + and 346 CD8 + cells. Cells were not stained with CD3 + antibodies to prevent non-specific cell activation. 347

Cells were then frozen and preserved in Trizol (Invitrogen). Total RNA was extracted from 348 10,000-50,000 cells and mRNA-sequencing libraries were generated as previously described. 54 349 Novaseq6000 was used for 50-cycle single-end read sequencing, which were processed with 350 bcl2fastq 2.17.1 to generate FastQ files. Reads were mapped to the human transcriptome hg19 351 using STAR 2.7.0; gene expression values (fpkm; fragments per kilobase exon per million 352 mapped reads) were calculated with RSEM 1.3.0 and normalized as previously described. 54 353 GSEA analysis was performed as described. 54 Enrichment score curves and member ranks were 354 generated by the GSEA software (Broad Institute). RNA-seq datasets were used in conjunction 355 with the following user-generated Gene Sets: (1) The functional profile of primary human antiviral CD8+ T cell effector activity is 551 dictated by cognate peptide concentration. The corresponding authors and colleagues demonstrate that manipulating cytokines during manufacture of coronavirus-specific T cells yields a markedly improved clinical product based upon cell yield, antiviral specificity, and type I interferon activity. They also provide methods for cytokine optimization of T cells targeting other viruses in the future.

Cancer patients in SARS-CoV-2 infection: a nationwide analysis 444 in China

Coronavirus 447 Disease 2019 in patients with inborn errors of immunity: an international study. The 448 Journal of allergy and clinical immunology

Outcomes of patients 451 with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 452 3377 patients

COVID-19 454 and Solid Organ Transplantation: A Review Article

COVID-19 in patients with primary and secondary immunodeficiency: The United 458 Kingdom experience

CoV-2: A Multicenter Study during the COVID-19 Outbreak

465 van den Akker

Phenotype and kinetics of SARS-CoV-2-specific T cells in 467 COVID-19 patients with acute respiratory distress syndrome

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 472 Disease and Unexposed Individuals

SARS-CoV-2-specific T cells are rapidly expanded for therapeutic use and target 477 conserved regions of the membrane protein

SARS-CoV-2-reactive T 481 cells in healthy donors and patients with COVID-19

Therapeutics Targeting Human Parainfluenza Virus 3 Are Broadly Epitope Specific and 574

Are Cross Reactive With Human Parainfluenza Virus 1. Front Immunol 11

Human 578 parainfluenza virus-3 can be targeted by rapidly ex vivo expanded T lymphocytes

Interleukin (IL) 582 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 583 receptor

Cell Dysfunction and Its Role in COVID-19

Flattening the COVID-19 Curve With 588 Natural Killer Cell Based Immunotherapies. Front Immunol 11

Integrative Bulk and Single-Cell 592 Profiling of Premanufacture T-cell Populations Reveals Factors Mediating Long-Term 593 Persistence of CAR T-cell Therapy

Author Correction: Determinants of response and resistance to CD19 chimeric antigen 598 receptor (CAR) T cell therapy of chronic lymphocytic leukemia

Transcriptional programs of neoantigen-602 specific TIL in anti-PD-1-treated lung cancers

CD8 T cells mediate response of adoptive cell immunotherapy against human cancer

Exposure of Human 609 CD8(+) T Cells to Type-2 Cytokines Impairs Division and Differentiation and Induces 610 Limited Polarization

Autoantibodies against type I IFNs in patients with life-threatening COVID-19

Inborn errors of type I IFN 617 immunity in patients with life-threatening COVID-19

Is IL-6 a key cytokine target for therapy in 620 COVID-19?

Clinical features of patients infected with 2019 novel 623 coronavirus in Wuhan

COVID-19: consider cytokine storm 626 syndromes and immunosuppression

Cytokine Levels in the Body Fluids of a Patient With COVID-19 and Acute Respiratory 630 Distress Syndrome: A Case Report

Pathogenic T-cells and inflammatory monocytes incite inflammatory 633 storms in severe COVID-19 patients

ALVR109, an off-the-shelf partially HLA matched SARS-CoV-2-specific T cell therapy, 637 to treat refractory severe COVID-19 pneumonia in a heart transplant patient: Case report

Retinoic Acid Receptor Alpha 641 Represses a Th9 Transcriptional and Epigenomic Program to Reduce Allergic Pathology

A. Absolute Counts of CD3 + T cells, CD4 + T cells, CD8 + T cells, and CD3 -CD56 + NK cells 654 on day 10. An approximation of fold expansion is provided in Supp Fig 4

Proportions of Naïve

+ T cell specificity as measured by absolute count of CD4 + IFN TNF + cells on day

CD8 + T cell specificity as measured by absolute count of CD8 + IFN TNF + cells on day

+ T cell specificity as measured by absolute count of CD3 + CD107a + cells on day 10

*Statistically significant, p<0.0125 corrected for multiple comparisons

Colors denote average log2(fold 670 change in gene expression) for cells cultured in cytokine-containing conditions vs. cells 671 cultured without cytokines. Selected enriched pathways and representative genes 672 (metascape) are shown for each module of DEGs

Heatmap displays 851 DEGs in CD8 + T cells cultured in at least one cytokine-containing 674

CD4 + T cells cultured without cytokines

Colors denote average log2 fold change in gene expression for cells 676 cultured in cytokine-containing conditions vs. cells cultured without cytokines. Selected 677 enriched pathways and representative genes (metascape) are shown for each module of 678

Scatterplot displays normalized enrichment scores (NES) and false discovery rate (FDR)

for an antiviral interferon stimulated gene cassette (Immunological Genome Project

Dashed line denotes a FDR of 10%. NES are shown for 682 each condition vs. all other conditions. Conditions where antiviral gene cassette is 683 significantly induced are marked in red; conditions where antiviral gene cassette is 684 significantly repressed are marked in blue

Scatterplot displays NES and false discovery rate FDR for an antiviral interferon 687 stimulated gene cassette

Dashed line denotes a FDR of 10%. NES are shown for each condition vs. all other 689 conditions. Conditions where antiviral gene cassette is significantly induced are marked 690 in red; conditions where antiviral gene cassette is significantly repressed are marked in 691 blue

Fold expansion of live cells following 10 day expansion

Proportions of Total T cells (CD3 + ), CD4 + T cells, CD8 + T cells, TCR β T cells, TCR 696 T cells, CD56 + CD3 -NK cells, CD19 + B cells, CD14 + monocytes after expansion

C. Proportion of CD3 + total T cells identified as: Naïve (CCR7 + , CD45RO -)

Effector Memory (CCR7 -, CD45RO + ), and Terminal

Effector (CCR7 -, CD45RO -) cells after expansion

D. CD4 + T cell specificity with differing cytokine conditions (IL-4+IL-7 vs IL-15+IL-7) as 701 measured by proportion of IFN + TNF + secreting cells

E. CD8 + T cell specificity with differing cytokine conditions (IL-4+IL-7 vs IL-15+IL-7) as 703 measured by proportion of IFN + TNF + secreting cells

F. CD3 + T cell specificity with differing cytokine conditions (IL-4+IL-7 vs IL-15+IL-7) as 705 measured by proportion of CD107a + expressing cells

Antiviral specificity of SARS-CoV-2 specific T cells (day 10) expanded with IL

IL-7+IL-15 to Spike and Membrane peptide libraries as measured by spot forming 708 units (SFU) per 100,000 cells on IFN ELIspot assay

** Statistically significant, p< .0125, corrected for multiple comparison for panel

Statistically significant, p<0.017, corrected for multiple comparison for panels (C) defense TNFRSF11A